数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
To investigate the mechanism of Shenqi Xiezhuo Decoction (SQXZD) for delaying progression of renal fibrosis (RF).
方法
Network pharmacology and molecular docking were used to identify the active components of SQXZD and their targets and pathways.
核心结论
Forty-nine male SD rats were randomly divided into control group, sham-operated group, unilateral ureteral obstruction (UUO)-induced RF model group, losartan (4.6 mg/kg) group, and low-, medium-, high-dose SQXZD (9.7, 19.4, and 38.8 g/kg, respectively) groups.；Renal tissues of the rats were collected to examine collagen distribution with Masson staining and detect expressions of E-cadherin, LC3B, p62/SQSTM1, and the ERK1/2-mTOR pathway.；In TGF-β1-induced NRK-49F and NRK-52E cells, the effects of blank rat serum, DMSO, SQXZD-medicated serum, digallic acid (DGA), SQXZD-medicated serum combined with U0126, or DGA combined with U0126 were assessed on autophagy levels and expressions of α‑SMA, collagen-I, E-eadherin, LC3B, p62/SQSTM1, and the ERK1/2-mTOR pathway.；The 54 active components (including 4-O-methylpaeoniflorin and DGA) identified… ‖ 结论：These changes were significantly reversed by treatment with SQXZD-medicated serum or DGA, either alone or in combination with U0126.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。DOI 未获 CrossRef 收录，建议按 PMID 在 PubMed 直接定位。
对本项目的价值
★★★☆☆ 营养感知与自噬轴决定"干预窗口 + 剂量方案"，是组合疗法的时间锚。
原文题录
- 英文标题：[Shenqi Xiezhuo Decoction ameliorates renal fibrosis in rats by inhibiting excessive autophagy via modulating the ERK1/2-mTOR signaling pathway].
- 期刊与标识：Nan Fang Yi Ke Da Xue Xue Bao · PMID 42934095 · DOI 10.12122/j.issn.1673-4254.2026.10.03**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。